Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. / Mathiesen, Line; Nielsen, Leif K; Andersen, Jan Terje; Grevys, Algirdas; Sandlie, Inger; Michaelsen, Terje E; Hedegaard, Morten; Knudsen, Lisbeth E.; Dziegiel, Morten Hanefeld.

In: Blood, Vol. 122, No. 7, 10.07.2013, p. 1174-1181.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Mathiesen, L, Nielsen, LK, Andersen, JT, Grevys, A, Sandlie, I, Michaelsen, TE, Hedegaard, M, Knudsen, LE & Dziegiel, MH 2013, 'Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions', Blood, vol. 122, no. 7, pp. 1174-1181. https://doi.org/10.1182/blood-2012-12-473843

APA

Mathiesen, L., Nielsen, L. K., Andersen, J. T., Grevys, A., Sandlie, I., Michaelsen, T. E., Hedegaard, M., Knudsen, L. E., & Dziegiel, M. H. (2013). Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood, 122(7), 1174-1181. https://doi.org/10.1182/blood-2012-12-473843

Vancouver

Mathiesen L, Nielsen LK, Andersen JT, Grevys A, Sandlie I, Michaelsen TE et al. Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood. 2013 Jul 10;122(7): 1174-1181. https://doi.org/10.1182/blood-2012-12-473843

Author

Mathiesen, Line ; Nielsen, Leif K ; Andersen, Jan Terje ; Grevys, Algirdas ; Sandlie, Inger ; Michaelsen, Terje E ; Hedegaard, Morten ; Knudsen, Lisbeth E. ; Dziegiel, Morten Hanefeld. / Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. In: Blood. 2013 ; Vol. 122, No. 7. pp. 1174-1181.

Bibtex

@article{6e62799f3d0a45648f21c218b1ad8468,
title = "Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions",
abstract = "The neonatal Fc receptor (FcRn) directs the transfer of maternal immunoglobulin G (IgG) antibodies across the placenta and thus provides the fetus and newborn with passive protective humoral immunity. Pathogenic maternal IgG antibodies will also be delivered via the placenta and can cause alloimmunity, which may be lethal. A novel strategy to control pathogenic antibodies would be administration of a non-destructive IgG antibody blocking antigen binding while retaining binding to FcRn. We report on two human IgG3 antibodies with a hinge deletion and a C131S point mutation (IgG3ΔHinge) that eliminate complement activation and binding to all classical Fcγ receptors (FcγRs) and to C1q while binding to FcRn is retained. Additionally, one of the antibodies has a single point mutation in the Fc (R435H) at the binding site for FcRn (IgG3ΔHinge:R435H). We compared transplacental transport with wild type IgG1 and IgG3, and found transport across trophoblast-derived BeWo cells and ex vivo placenta perfusions with hierarchies as follows: IgG3ΔHinge:R435H>wild type IgG1≥IgG3ΔHinge, and IgG3ΔHinge:R435H=wild type IgG1=wild type IgG3>IgG3ΔHinge, respectively. Collectively, IgG3ΔHinge:R435H was transported efficiently from the maternal to the fetal placental compartment. Thus, IgG3ΔHinge:R435H may be a good candidate for transplacental delivery of a non-destructive antibody to the fetus to combat pathogenic antibodies.",
author = "Line Mathiesen and Nielsen, {Leif K} and Andersen, {Jan Terje} and Algirdas Grevys and Inger Sandlie and Michaelsen, {Terje E} and Morten Hedegaard and Knudsen, {Lisbeth E.} and Dziegiel, {Morten Hanefeld}",
year = "2013",
month = jul,
day = "10",
doi = "10.1182/blood-2012-12-473843",
language = "English",
volume = "122",
pages = " 1174--1181",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

RIS

TY - JOUR

T1 - Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions

AU - Mathiesen, Line

AU - Nielsen, Leif K

AU - Andersen, Jan Terje

AU - Grevys, Algirdas

AU - Sandlie, Inger

AU - Michaelsen, Terje E

AU - Hedegaard, Morten

AU - Knudsen, Lisbeth E.

AU - Dziegiel, Morten Hanefeld

PY - 2013/7/10

Y1 - 2013/7/10

N2 - The neonatal Fc receptor (FcRn) directs the transfer of maternal immunoglobulin G (IgG) antibodies across the placenta and thus provides the fetus and newborn with passive protective humoral immunity. Pathogenic maternal IgG antibodies will also be delivered via the placenta and can cause alloimmunity, which may be lethal. A novel strategy to control pathogenic antibodies would be administration of a non-destructive IgG antibody blocking antigen binding while retaining binding to FcRn. We report on two human IgG3 antibodies with a hinge deletion and a C131S point mutation (IgG3ΔHinge) that eliminate complement activation and binding to all classical Fcγ receptors (FcγRs) and to C1q while binding to FcRn is retained. Additionally, one of the antibodies has a single point mutation in the Fc (R435H) at the binding site for FcRn (IgG3ΔHinge:R435H). We compared transplacental transport with wild type IgG1 and IgG3, and found transport across trophoblast-derived BeWo cells and ex vivo placenta perfusions with hierarchies as follows: IgG3ΔHinge:R435H>wild type IgG1≥IgG3ΔHinge, and IgG3ΔHinge:R435H=wild type IgG1=wild type IgG3>IgG3ΔHinge, respectively. Collectively, IgG3ΔHinge:R435H was transported efficiently from the maternal to the fetal placental compartment. Thus, IgG3ΔHinge:R435H may be a good candidate for transplacental delivery of a non-destructive antibody to the fetus to combat pathogenic antibodies.

AB - The neonatal Fc receptor (FcRn) directs the transfer of maternal immunoglobulin G (IgG) antibodies across the placenta and thus provides the fetus and newborn with passive protective humoral immunity. Pathogenic maternal IgG antibodies will also be delivered via the placenta and can cause alloimmunity, which may be lethal. A novel strategy to control pathogenic antibodies would be administration of a non-destructive IgG antibody blocking antigen binding while retaining binding to FcRn. We report on two human IgG3 antibodies with a hinge deletion and a C131S point mutation (IgG3ΔHinge) that eliminate complement activation and binding to all classical Fcγ receptors (FcγRs) and to C1q while binding to FcRn is retained. Additionally, one of the antibodies has a single point mutation in the Fc (R435H) at the binding site for FcRn (IgG3ΔHinge:R435H). We compared transplacental transport with wild type IgG1 and IgG3, and found transport across trophoblast-derived BeWo cells and ex vivo placenta perfusions with hierarchies as follows: IgG3ΔHinge:R435H>wild type IgG1≥IgG3ΔHinge, and IgG3ΔHinge:R435H=wild type IgG1=wild type IgG3>IgG3ΔHinge, respectively. Collectively, IgG3ΔHinge:R435H was transported efficiently from the maternal to the fetal placental compartment. Thus, IgG3ΔHinge:R435H may be a good candidate for transplacental delivery of a non-destructive antibody to the fetus to combat pathogenic antibodies.

U2 - 10.1182/blood-2012-12-473843

DO - 10.1182/blood-2012-12-473843

M3 - Journal article

C2 - 23843496

VL - 122

SP - 1174

EP - 1181

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -

ID: 47553258